Clearside Biomedical Inc. (CLSD)
0.97
-0.06 (-5.83%)
At close: Mar 28, 2025, 3:59 PM
0.97
0.45%
Pre-market: Mar 31, 2025, 04:02 AM EDT
-5.83% (1D)
| Bid | 0.8 |
| Market Cap | 73.55M |
| Revenue (ttm) | 7.82M |
| Net Income (ttm) | -32.35M |
| EPS (ttm) | -0.45 |
| PE Ratio (ttm) | -2.15 |
| Forward PE | -2.1 |
| Analyst | Buy |
| Ask | 1.15 |
| Volume | 285,486 |
| Avg. Volume (20D) | 212,826 |
| Open | 0.98 |
| Previous Close | 1.03 |
| Day's Range | 0.94 - 1.03 |
| 52-Week Range | 0.77 - 1.65 |
| Beta | 2.10 |
About CLSD
Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase 1/2a clinical trial; and CLS-301, an i...
Industry Biotechnology
Sector Healthcare
IPO Date Jun 2, 2016
Employees 30
Stock Exchange NASDAQ
Ticker Symbol CLSD
Website https://www.clearsidebio.com
Analyst Forecast
According to 5 analyst ratings, the average rating for CLSD stock is "Buy." The 12-month stock price forecast is $5, which is an increase of 415.62% from the latest price.
Stock ForecastsEarnings Surprise
Clearside Biomedical has released their quartely earnings
on Mar 27, 2025:
Next Earnings Release
Clearside Biomedical Inc. is scheduled to release its earnings on May 8, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
3 weeks ago
+14.82%
Clearside Biomedical shares are trading higher aft...
Unlock content with
Pro Subscription
9 months ago
+15.74%
Clearside Biomedical shares are trading higher after Oppenheimer initiated coverage with an Outperform rating and a price target of $5.
